EVOLOCUMAB USE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS AND DYSLIPIDEMIA: PRIMARY RESULTS OF A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (BEIJERINCK)
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)32459-1
Abstract: People living with human immunodeficiency virus (PLHIV) are at increased risk of cardiovascular disease due to metabolic abnormalities, chronic inflammation and immune dysregulation. PLHIV may receive suboptimal lipid-lowering therapy because of drug-drug interactions between high-intensity… read more here.
Keywords: evolocumab use; human immunodeficiency; use patients; immunodeficiency virus ... See more keywords
Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study
Sign Up to like & getrecommendations! Published in 2024 at "Therapeutic Advances in Cardiovascular Disease"
DOI: 10.1177/17539447231213288
Abstract: Aims: The HEYMANS study observed patients receiving evolocumab as part of routine clinical hyperlipidemia management. It was designed to capture data on clinical parameters relevant to health authorities and physicians. Methods: This was a European… read more here.
Keywords: cohort; practice; clinical practice; evolocumab use ... See more keywords